A Chemotherapy-Free Regimen of Tucatinib and Trastuzumab Shows Antitumour Activity with Durable Responses in Patients with HER2-mutated MBC By Ogkologos - January 29, 2025 532 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SGNTUC-019 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR First targeted treatment approved for advanced prostate cancer on NHS in... October 13, 2021 Daughter Donates Hair to Mother After She Was Diagnosed with Stage... March 3, 2021 Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer June 30, 2025 Cancer Research UK reports record levels of investment in its spinouts August 24, 2021 Load more HOT NEWS A peek behind the scenes: Just how are our funding decisions... NICE doesn’t recommend olaparib for patients with certain prostate cancers ASCO Annual Meeting 2023: Trastuzumab Deruxtecan Effectively Treats HER2-Expressing Tumors and... Cuando necesita ayuda con responsabilidades de cuidado
